Issue #3 2016 – Digital edition
In this issue: Biosimilars, Regulation, Packaging, Microfluidics, Microbiology, PAT, Antibiotic Resistance, and much more...
List view / Grid view
Articles
Microbiology: In-Depth Focus 2016
In this Microbiology In-Depth Focus: Risk-based microbiological testing; Improving microbiological assurance for bioburden testing; Microbiology Roundtable...
Pharmaceutical Packaging In-Depth Focus 2016
In this Pharmaceutical Packaging In-Depth Focus: End-to-end verification of the medicines supply chain; Understanding the financial implications of the upcoming falsified medicines regulations; Point of view on the evolution of labelling and packaging.
Biosimilars – future prospects
Biologically-derived drugs, such as proteins, peptides and monoclonal antibodies (mABs), are playing an increasingly important role in global healthcare. It was recently reported that mAB therapeutics sell for over $50 billion globally. However, one of the major downsides of biological therapeutics is their significantly greater costs compared with small molecule…
Regulatory Insight: Pharma sector – long a target for antitrust enforcers
Many features of the pharmaceutical sector make it prone to antitrust scrutiny. Intellectual property rights, in particular patents, and the promise of monopoly rents while patents remain valid, play a crucial role in incentivising new product research and development. On the other hand, the European Commission and the various national…
Microfluidics in cell-to-cell signalling measurements
Hormones are secreted molecules that carry biological information between cells. This type of cell-to-cell communication is vital to human life, and its dysregulation often underlies disease. In fact, the largest known class of cell surface receptors involved in hormone communication, G-protein coupled receptors, are also the largest class of known…
PAT Series: Recent achievements in NIR-based on-line monitoring of lyophilisation processes
30 June 2016 | By Adrian Funke - Bayer Pharma AG / Reinhard Gross, Stephan Tosch and Albert Tulke - Bayer Technology GmbH
Process analytical technology (PAT), namely near-infrared (NIR) and Raman spectroscopy, has already been shown to be a useful tool for monitoring, analysing and optimising the complex process of lyophilisation. The latter process is especially challenging in the case of biopharmaceutical formulations due to the instability of active ingredients, leading to…
Antibiotics resistance Q&A
With the rise in drug-resistant bacterial infections heralding a new, dark era of medicine, antibiotics alternatives could one day become the first-line defence against infectious diseases. With the urgent need to find new approaches clear, Caroline Richards, Editor of European Pharmaceutical Review, interviewed Dr. Bjorn Herpers, Chief Medical Advisor of…
EU Referendum: Tell us what you think…
20 June 2016 | By Caroline Richards, Editor, European Pharmaceutical Review
With only days to go until Britain holds a referendum on its EU membership, we can't help but wonder how you feel...
Growth remedy: Accelerating drug performance by prioritising patient opportunities
13 June 2016 | By Joaquim Nascimento
In this article, Joaquim Nascimento discusses a three-step process to identify and prioritise initiatives to improve drug sales...
Leaving EU could be a setback for Life Sciences in the UK
8 June 2016 | By Dr Alexander Moscho, Bayer UK & Ireland CEO
In this opinion piece, Dr Alexander Moscho, Bayer UK & Ireland CEO, says a vote to leave the EU will deter investment and make it harder for patients to access new medicines...
Boehringer Ingelheim at ASCO: Oncology and Innovation
6 June 2016 | By Victoria White, Digital Content Producer
We recently caught up with Dr Jörg Barth, Boehringer Ingelheim, to find out more about the company’s oncology pipeline and presence at ASCO....
Soligenix on IDR technology and SGX942
10 May 2016 | By Victoria White, Digital Content Producer
We discuss Innate Defense Regulator (IDR) technology with Soligenix's Chief Scientific Officer, Dr Oreola Donini, and find out more about SGX942...
AZP-531 and its potential in Prader-Willi Syndrome
9 May 2016 | By Victoria White, Digital Content Producer
In this exclusive interview, Thierry Abribat, president of Alizé Pharma, discusses AZP-531 and its potential as a treatment for Prader-Willi Syndrome...
Issue #2 2016 – Digital edition
In this issue: Regulation, Oncology, Single Use, Robotics, Microbiology, PAT, Mass Spectrometry, Drug Delivery, Nanotechnology, and much more...
